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TO THE EDITOR
Generalized vitiligo (GV) is a common
autoimmune disease resulting from
the destruction of melanocytes in the
involved areas, epidemiologically asso-
ciated with elevated prevalence of
certain other autoimmune diseases
(Picardo and Taı¨eb, 2010). In a
recent genome-wide association study
(GWAS) of GV, carried out in Euro-
pean-derived whites (EUR), we identi-
fied 16 loci that contribute to GV risk
(Jin et al., 2010a,b; Birlea et al., 2011).
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Figure 2. Genealogical trees, skin lesions in families 1 and 2, and differently spliced transcripts of NCSTN
in family 3. ‘‘þ ’’ Indicates family members who were examined and sequenced. (a) Pedigree 1; (b)
hypertrophic scars and nodules of the groin. (c) Pedigree 2; (d) hypertrophic scars and fistulas of the buttocks.
(e) Pedigree 3; (f) three different transcripts were identified in the proband of family 3: a wild-type transcript
(WT) and two transcripts derived from the c.1768A4G mutation: D26, resulting from a 26-bp deletion of
exon 15 and D114, harboring a 26-bp deletion of exon 15 and an 88-bp deletion of exon 16. Newly
activated acceptor (AG) and donor (GT) cryptic slice sites are highlighted in blue.
Abbreviations: EUR, European-derived whites; GV, generalized vitiligo; GWAS, genome-wide
association study; MHC, major histocompatibility complex; OCA1, oculocutaneous albinism type 1;
OR, odds ratio; SNP, single-nucleotide polymorphism; TYR, tyrosinase (gene or protein)
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Within the major histocompatibility
complex (MHC), a major GV associa-
tion signal localized to HLA-A, in the
class I gene region. Outside the MHC,
the strongest GV association was with
TYR, which encodes tyrosinase (TYR).
At HLA-A, the most highly associated
single-nucleotide polymorphism (SNP)
was rs12206499 (P¼1.24 1019,
odds ratio (OR)¼1.58), which tags
HLA-A*02 (r2¼0.964, D0 ¼1.0) in the
EUR population (Jin et al., 2010a). At
TYR, the strongest association was with
rs1393350 (P¼3.24 1013, OR¼
0.65), which is in linkage disequilibrium
(r2¼0.79. D0 ¼1) with a common non-
synonymous TYR variant, R402Q
(rs1126809; Giebel et al., 1991). TYR is
the major GV autoimmune antigen (Song
et al., 1994), and TYR peptide antigens
are predominantly presented on the
melanocyte surface by HLA-A*02:01
(Brichard et al., 1993). The TYR R402Q
substitution results in a temperature-
sensitive tyrosinase TYR polypeptide
(Tripathi et al., 1991) that is retained in
the endoplasmic reticulum, is hypogly-
cosylated, and is preferentially degraded
(Toyofuku et al., 2001). We therefore
suggested that TYR R402Q might protect
from GV by reducing the availability of
TYR peptide for antigen presentation by
HLA*02:01 (Jin et al., 2010a).
To specifically define the HLA-A
subtype associated with GV, we per-
formed next-generation DNA re-sequenc-
ing of HLA-A exons 2, 3, and 4, which
contain the sequence variations that
define HLA-A subtypes (http://www.e-
bi.ac.uk/imgt/hla/), in 20 unrelated EUR
GV patients. To maximize information,
each patient was selected on the basis
of homozygosity for rs12206499-G,
which tags the GV-associated HLA-
A*02 type (r2¼0.964, D0 ¼1.0) in the
EUR population (Jin et al., 2010a).
As shown in Supplementary Table S1
online, of the 20 patients sequenced,
18 were homozygous HLA-A*02:01/
*02:01, 1 was heterozygous HLA-
A*02:01/*02:20:01, and 1 was HLA-
A*02:06:01/*02:30. (The allelic typing
system does not distinguish between
the common HLA-A*02:01:01:01
allele and the very rare HLA-
A*02:01:01:02L allele; to be conserva-
tive, here we represent these alleles
using the standard four-digit nomencla-
ture, HLA-A*02:01). This distribution of
HLA-A*02 subtypes is similar to that in
EUR control populations (http://www.
ncbi.nlm.nih.gov/gv/mhc/main.cgi?cmd=
init; http://www.allelefrequencies.net/),
indicating that the predominant HLA-
A*02 GV risk subtype is HLA-A*02:01.
To specifically identify TYR gene
variants associated with GV, we carried
out next-generation re-sequencing of
10.4 kb across the TYR locus, including
2.4 kb of promoter, the five exons and
adjacent intron sequences, and 3.2 kb
downstream, in 114 unrelated EUR GV
patients. As shown in Supplementary
Table S2 online, we identified 31 SNPs,
with no indels or other rearrangements.
Bioinformatic analyses predicted that
only three of these are functionally
significant. One, rs61754388 (T373K), is
a known oculocutaneous albinism type 1
(OCA1) mutation (Spritz et al., 1990),
seen in a single heterozygote, consistent
with the expected carrier frequency of
OCA1. The other two, rs1042602
(S192Y) and rs1126809 (R402Q), are
common non-synonymous polymorph-
isms (Giebel and Spritz, 1990; Giebel
et al., 1991) that occur almost exclusively
in EUR populations (http://www.ncbi.
nlm.nih.gov/projects/SNP/).
In the GWAS, imputed rs1126809
genotypes demonstrated strongly pro-
tective association of the variant A
allele with GV (P¼1.36 1014, OR¼
0.65), whereas rs1042602 showed
no association (P¼ 0.611, OR¼0.98).
However, when both variants were
considered simultaneously by logistic
regression (Table 1A), rs1042602 was
also significantly associated with GV
(P¼1.23 104); when analyzed indi-
vidually, association of rs1042602 was
masked because its protective allele A
is in linkage disequilibrium with the
risk allele G of rs1126809; r2 between
the two SNPs is 0.15. Furthermore,
Table 1. Association of GV with non-synonymous TYR rs1042602 and rs1126809 variants and haplotypes
SNP Minor allele
Frequency
in cases
Frequency
in controls
Nominal
P-value OR
P-value conditional
on rs1126809
P-value conditional
on rs1042602
A. Association with individual variants
rs1042602 (S192Y) A 0.36 0.37 0.611 0.98 1.23 104
rs1126809 (R402Q) A 0.21 0.29 1.36 1014 0.65 1.04 1017
Haplotype C-G A-G C-A A-A Overall
B. Association with rs1042602-rs1126809 haplotypes
Frequency 0.39 0.35 0.25 0.01
OR 1.01 0.83 0.61 0.27
P 6.74104 2.02 1015 5.82 104 3.76 1017
Abbreviations: GV, generalized vitiligo; OR, odds ratio.
1The ancestral C-G haplotype was used as the reference, with OR defined as 1.0, and thus was not included the model.
The ORs and P-values were calculated with the additive effects of haplotypes A-A, C-A, and A-G included in the same model.
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haplotype analysis of rs1042602 and
rs1126809 (Table 1B) showed that, com-
pared with the ancestral reference
haplotype C-G, the other three
rs1042602-rs1126809 variant haplotypes
define a protective haplotypic series, the
double-variant A-A haplotype reducing
GV risk 3.7-fold: A-G, OR 0.83; C-A, OR
0.61; and A-A, OR 0.27. The overall
P-value for a model including the additive
effects of each haplotype is 3.761017
(including dominance effects in the mod-
el did not improve significance; Supple-
mentary Table S3 online).
To assess possible contributions of
other deleterious TYR variants to GV
risk, we imputed SNP genotypes across
334 kb of the TYR region of 11q14.3
based on 1000 Genome Project EUR
data (http://www.1000genomes.org/
data). While many SNPs (MAF40.01)
showed significant association with GV
(Supplementary Table S4 online), logis-
tic regression analysis showed that
none remained significant after condi-
tioning on rs1126809 or on rs1126809
plus rs1042602. Together with the
absence of rare predicted deleterious
variants observed by sequencing, this
suggests that rs1126809 and rs1042602
likely account for most genetic associa-
tion of GV with common TYR variants
in the EUR population.
Together, HLA-A*02:01 and TYR
mediate one of the principal pathways
of immune recognition of melano-
cytes by autoreactive CTL. One of the
major melanocyte autoantigens is TYR,
of which degradation peptides are
presented as antigenic epitopes on the
melanocyte surface, principally by
HLA-A*02:01 (Brichard et al., 1993),
consistent with our sequencing results
identifying HLA-A*02:01 as the predo-
minant GV-associated HLA-A*02 sub-
type. The best-studied HLA-A*02-
restricted TYR antigenic epitope is
TYR369-377 (YMDGTMSQV), of which
residue D371 derives from deamidation
of N371 on removal of an N-linked
oligosaccharide (Skipper et al., 1996), a
modification required for efficient
presentation by HLA-A*02:01 (Skipper
et al., 1996). However, N-glycosylation
of R402Q TYR is greatly reduced at
37 1C (Toyofuku et al., 2001), likely
preventing the subsequent N-deglycosy-
lation-dependent N371D modification,
reducing antigenic presentation by HLA-
A*02:01, reducing target-cell recognition
by melanocyte-specific CTL, and thus
protecting from GV. Although not yet
studied experimentally, the biological
consequences of the TYR S192Y sub-
stitution may be analogous to those of
R402Q.
The TYR S192Y and R402Q variants
occur essentially only in EUR-derived
populations. Similarly, HLA-A*02:01 is
common in EUR-derived populations,
but is far less frequent in Asia, perhaps
explaining why association signals at
neither HLA-A nor TYR were observed
in a GWAS of GV in Chinese (Quan
et al., 2010). Nevertheless, TYR may
have an important role in the pathogen-
esis of GV in many or all populations,
but the lack of functional TYR variation
outside of EUR populations may preclude
the ability to detect genetic association
with GV in non-EUR populations.
The TYR R402Q variant, while
protective for GV, is conversely asso-
ciated with increased risk of malignant
melanoma (reviewed in Spritz, 2010).
Moreover, HLA-A*02:01, although
associated with increased risk of GV,
is associated with relatively good
response to melanoma immunotherapy
(Mitchell et al., 1992), which depends
on presentation and recognition of
melanocyte antigens. Together, the
opposite genetic influences of HLA-
A*02:01 and TYR with respect to GV
versus malignant melanoma suggest
that both findings may relate to a com-
mon underlying mechanism, in which
TYR S192Y and R402Q haplotypes
modulate the amount of TYR presenta-
tion by HLA-A*02:01, thereby modulat-
ing recognition of melanocytes by
autoreactive CTL. Constitutive low-
level autoimmunity may be part of a
normal mechanism of immune surveil-
lance to detect and destroy neoplastic
melanocytes, whereas in GV dysregula-
tion of this mechanism might lead to
immune targeting and destruction of
normal melanocytes (Spritz, 2010). This
may have significant implications for
the utility of suppressing the HLA-
A-TYR pathway as a treatment for GV,
as doing so might thus increase the risk
of malignant melanoma.
All participants provided written,
informed consent to participate in the
study, which was approved by the
Colorado Multiple Institutional Review
Board (COMIRB) at the University of
Colorado Denver. The study com-
plied with Declaration of Helsinki
principles.
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TO THE EDITOR
Kaposi sarcoma herpesvirus (KSHV) is a
newly identified human herpesvirus
(Chang et al., 1994) and the primary
etiologic agent of Kaposi’s sarcoma
(Gallo, 1998). The entry of KSHV into
cells is a well-orchestrated event yet to
be understood in its entirety. The most
common mucosal site where infectious
KSHV particles have been detected is
the oropharynx, where viable viral par-
ticles are shed into the saliva (Webster-
Cyriaque et al., 2006), which appears
to be a possible source of virus for new
infections (Plancoulaine et al., 2000)
with saliva-borne virions demonstrated
to be infectious (Pauk et al., 2000).
Saliva is a dilute aqueous solution that
lubricates and protects the oral cavity
and provides nonimmune defense
against pathogens (Wu et al., 1994).
Indeed, a high KSHV load was mea-
sured in the oral compartment, which
appeared to be independent from KSHV
titers in the peripheral blood mono-
nuclear cells (Marcelin et al., 2004).
Previously, we demonstrated KSHV to
specifically interact with human lacto-
ferrin (hLf) from saliva, and more
particularly with a non-glycosylated
8-kDa-derived peptide (Grange et al.,
2005). However, the possible role of
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Figure 1. Human lactoferrin (hLf) enhances Kaposi sarcoma herpesvirus (KSHV) infection. Target cells
were incubated for 1 hour at 37 1C with various concentrations of hLf and infected at a multiplicity of
infection (MOI) of 1 ORF73 units of rKSHV.152. (a) Total number of green fluorescent protein (GFP)-
positive cells indicative of infection in each well was counted under a fluorescent microscope at 72 hours
post infection (hPI), and (b) at 3 hPI, internalized KSHV particles were calculated from the corresponding
copy numbers of ORF50 gene determined by quantitative PCR (qPCR). The actual copy numbers of
ORF50 gene detected in hLf-untreated 293 and primary human foreskin fibroblast (HFF) cells were
375±50 and 95±10, respectively. These numbers were considered as 1-fold. Data represent the average
±SD of three independent experiments. Columns with different letters (a–f) are statistically significant
(Po0.05) by least significant difference (LSD).
Abbreviations: GFP, green fluorescent protein; HFF, primary human foreskin fibroblast; hLf, human
lactoferrin; hPI, hours post infection; KSHV, Kaposi sarcoma herpesvirus; qPCR, quantitative PCR
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Inhibition of KSHV Infection
